12 Analysts Have This to Say About Cognizant Tech Solns

Analysts have provided the following ratings for Cognizant Tech Solns (NASDAQ:CTSH) within the last quarter:

Analysts have provided the following ratings for Cognizant Tech Solns (NASDAQ:CTSH) within the last quarter:

  Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish
Total Ratings 0 4 7 1 0
Last 30D 0 0 1 0 0
1M Ago 0 1 1 0 0
2M Ago 0 0 0 0 0
3M Ago 0 3 5 1 0

These 12 analysts have an average price target of $74.33 versus the current price of Cognizant Tech Solns at $59.125, implying upside.

Below is a summary of how these 12 analysts rated Cognizant Tech Solns over the past 3 months. The greater the number of bullish ratings, the more positive analysts are on the stock and the greater the number of bearish ratings, the more negative analysts are on the stock

price target chart

This current average has decreased by 12.98% from the previous average price target of $85.42.

Stay up to date on Cognizant Tech Solns analyst ratings.

Analyst Ratings: What Are They?

Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish “analyst ratings” for stocks. Analysts typically rate each stock once per quarter.

Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.

This article was generated by Benzinga’s automated content engine and reviewed by an editor.

Total
0
Shares
Related Posts
Read More

Apple Avoids Layoffs, Dogecoin Surges, South America Does A Eurozone And More: 5 Key Stories You May Have Missed From The Weekend

As the fourth-quarter reporting season starts in earnest this week, chatter over the weekend focused on its impact on the fledgling recovery seen in the market. Discussions also centered around the odds of a recession materializing and the likely monetary policy stance of the Federal Reserve when it meets at the end of the month.

$DOGE

Read More

Blindness-Focused LENZ Therapeutics’ Investigational Eye Drop Ready To Revolutionize Presbyopia Landscape, Analyst Says

Advances in presbyopia treatment with LENZ Therapeutics' LNZ100. Clinically proven to enhance near-vision for up to 10 hours, it offers a promising alternative to reading glasses. Analysts predict a bright future with a Buy rating and $34 price target.

ABBV